Covid-19: Politicisation, “Corruption,” and Suppression of Science
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Spotlight Briefing Note
Spotlight briefing Responding to the COVID-19 pandemic Ten questions on the next phase of the UK’s COVID-19 response October 2020 Overview • There are a number of questions which remain as to the next phase of the response to the COVID-19 pandemic. • What values have informed the most recent decisions on COVID-19 restrictions? Public health measures involve a number of challenging trade-offs between different rights and interests. Alongside the scientific evidence, it must be made clear which values are guiding decisions about which, and whose, interests take priority, and why. • Is the government considering the use of “immunity certificates” in the next phase of the response? Any approach which relies on a system of ‘immunity certification’ raises a number of ethical questions concerning individual rights versus the public interest, and social justice. If the Government is considering such a system, there must be a robust and open debate now. • How will development of an effective COVID-19 vaccine affect uptake - and what should be done? Issues around the speed of development, changes in regulation, and communication with the public may all affect public trust and uptake of any vaccine. Consideration about how to address these issues should take place now. • What discussions are taking place on setting priorities for vaccine allocation within the UK? There is a range of different values which can be taken into consideration when setting priorities for access to limited doses of a vaccine. What values and interests will guide decision-making in this area must be clearly set out. • How will the UK ensure a sustained commitment to global solidarity? The global nature of the pandemic shows the importance of working as part of a global effort. -
Whole Day Download the Hansard
Monday Volume 681 28 September 2020 No. 109 HOUSE OF COMMONS OFFICIAL REPORT PARLIAMENTARY DEBATES (HANSARD) Monday 28 September 2020 © Parliamentary Copyright House of Commons 2020 This publication may be reproduced under the terms of the Open Parliament licence, which is published at www.parliament.uk/site-information/copyright/. HER MAJESTY’S GOVERNMENT MEMBERS OF THE CABINET (FORMED BY THE RT HON. BORIS JOHNSON, MP, DECEMBER 2019) PRIME MINISTER,FIRST LORD OF THE TREASURY,MINISTER FOR THE CIVIL SERVICE AND MINISTER FOR THE UNION— The Rt Hon. Boris Johnson, MP CHANCELLOR OF THE EXCHEQUER—The Rt Hon. Rishi Sunak, MP SECRETARY OF STATE FOR FOREIGN,COMMONWEALTH AND DEVELOPMENT AFFAIRS AND FIRST SECRETARY OF STATE— The Rt Hon. Dominic Raab, MP SECRETARY OF STATE FOR THE HOME DEPARTMENT—The Rt Hon. Priti Patel, MP CHANCELLOR OF THE DUCHY OF LANCASTER AND MINISTER FOR THE CABINET OFFICE—The Rt Hon. Michael Gove, MP LORD CHANCELLOR AND SECRETARY OF STATE FOR JUSTICE—The Rt Hon. Robert Buckland, QC, MP SECRETARY OF STATE FOR DEFENCE—The Rt Hon. Ben Wallace, MP SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE—The Rt Hon. Matt Hancock, MP SECRETARY OF STATE FOR BUSINESS,ENERGY AND INDUSTRIAL STRATEGY—The Rt Hon. Alok Sharma, MP SECRETARY OF STATE FOR INTERNATIONAL TRADE AND PRESIDENT OF THE BOARD OF TRADE, AND MINISTER FOR WOMEN AND EQUALITIES—The Rt Hon. Elizabeth Truss, MP SECRETARY OF STATE FOR WORK AND PENSIONS—The Rt Hon. Dr Thérèse Coffey, MP SECRETARY OF STATE FOR EDUCATION—The Rt Hon. Gavin Williamson CBE, MP SECRETARY OF STATE FOR ENVIRONMENT,FOOD AND RURAL AFFAIRS—The Rt Hon. -
COVID-19: Make It the Last Pandemic
COVID-19: Make it the Last Pandemic Disclaimer: The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Independent Panel for Pandemic Preparedness and Response concerning the legal status of any country, territory, city of area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Report Design: Michelle Hopgood, Toronto, Canada Icon Illustrator: Janet McLeod Wortel Maps: Taylor Blake COVID-19: Make it the Last Pandemic by The Independent Panel for Pandemic Preparedness & Response 2 of 86 Contents Preface 4 Abbreviations 6 1. Introduction 8 2. The devastating reality of the COVID-19 pandemic 10 3. The Panel’s call for immediate actions to stop the COVID-19 pandemic 12 4. What happened, what we’ve learned and what needs to change 15 4.1 Before the pandemic — the failure to take preparation seriously 15 4.2 A virus moving faster than the surveillance and alert system 21 4.2.1 The first reported cases 22 4.2.2 The declaration of a public health emergency of international concern 24 4.2.3 Two worlds at different speeds 26 4.3 Early responses lacked urgency and effectiveness 28 4.3.1 Successful countries were proactive, unsuccessful ones denied and delayed 31 4.3.2 The crisis in supplies 33 4.3.3 Lessons to be learnt from the early response 36 4.4 The failure to sustain the response in the face of the crisis 38 4.4.1 National health systems under enormous stress 38 4.4.2 Jobs at risk 38 4.4.3 Vaccine nationalism 41 5. -
Letter Tony Nikolic Wrote to New South Wales Minister
4. I am instructed to send this letter to sitting Members of Parliament (State and Federal). 5. The most recent Orders from the NSW State Government on Airport workers at Kingsford Smith Airport (Sydney) has caused a number of airport employees (including pregnant and single wage families/adults) to go on stress leave because they have been given an ultimatum to get the vaccine or potentially lose their positions. The amount of emails and calls from airline industry staff to my office is most concerning and I am instructed to make this representation on their behalf because they believe their elected representatives are not taking notice. 6. We are also mindful that the airport staff, front-line workers, pilots, police, paramedics and medical staff are also seeking the protection of all rights and responsibilities pursuant to Australian and International laws. 7. There are people taking sick leave from airport duties due to the mental health related issues and pressures being placed on them to take a vaccine. We understand that that the Australian Government cannot guarantee the vaccines safety in the short, mid and long term, but yet the NSW Government are issuing Orders for companies to vaccinate all staff, whilst Federal Parliamentarians do not question the validity or acknowledge this growing concern in electorates all over Australia. 8. I am instructed those workers are not allowed on Commonwealth airport property effective as of 6 July 2021 as a result of State Orders. The workers are not only feeling the pressures imposed upon them with speed and stealth at which the Orders were passed, but they are also concerned about being targeted if they speak out. -
BMJ in the News Is a Weekly Digest of Journal Stories, Plus Any Other News
BMJ in the News is a weekly digest of journal stories, plus any other news about the company that has appeared in the national and a selection of English-speaking international media. A total of 25 journals were picked up in the media last week (21-27 September) - our highlights include: ● Research in The BMJ on excess belly fat and risk of early death was covered widely, including CNN, The Daily Mail and The Daily Telegraph. ● The New York Times ran an op-ed by Peter Doshi, Associate Editor at The BMJ on covid-19 vaccine trials. ● Research in Thorax warning that patients with no symptoms carry as much covid-19 virus as those with symptoms generated global headlines, including NBC News, New York Daily News and The Guardian. BMJ PRESS RELEASES The BMJ | BMJ Open Open Heart | Thorax EXTERNAL PRESS RELEASES BMJ Open | BMJ Open Diabetes Research & Care British Journal of Sports Medicine | Emergency Medicine Journal OTHER COVERAGE The BMJ | Annals of the Rheumatic Diseases Archives of Disease in Childhood | BMJ Evidence-Based Medicine BMJ Global Health | BMJ Nutrition, Prevention & Health BMJ Open Respiratory Research | Frontline Gastroenterology Gut | Heart Injury Prevention | Journal of Epidemiology & Community Health Journal of Medical Ethics | Journal of Neurology, Neurosurgery & Psychiatry Medical Humanities | Occupational & Environmental Medicine Postgraduate Medical Journal | Practical Neurology Vet Record B MJ New Co-Editors-in-Chief for BMJ Quality -
WHO Backs Rollout of Astrazeneca Vaccine
this week TWINS page 423 • VACCINATING CHILDREN page 424 • BRITISH CYCLING page 427 FRANK HOERMANN/DPA/PA/ALAMY FRANK WHO backs rollout of AstraZeneca vaccine Doctors have warned of the risks associated On 16 March WHO’s chief scientist, Soumya The World Health Organization with pausing or delaying vaccination Swaminathan, said, “We do not want has urged people not to panic programmes against covid-19, as the people to panic, and we would, for the time amid reports of blood clotting number of European countries that have being, recommend that countries continue disorders in patients receiving the vaccine halted use of the Oxford University and vaccinating with AstraZeneca . So far, we AstraZeneca vaccine rose to 16. do not fi nd an association between these Denmark, Norway, Bulgaria, Iceland, events and the vaccine.” France, Germany, Italy, Spain, Portugal, The EMA said there had been 30 reports Slovenia, and Cyprus have suspended all of thromboembolic events among nearly use of the vaccine. Five other countries fi ve million people given the AstraZeneca (Austria, Estonia, Latvia, Lithuania, and vaccine in the European Economic Area. Luxembourg) have paused the use of a AstraZeneca has said 37 blood clots have LATEST ONLINE batch of a million doses of the vaccine. been reported among more than 17 million NHS and social The moves came after reports of people vaccinated in the EU and Britain. care need an extra blood clotting disorders. The Norwegian Five of the cases were deep vein thrombosis, £12bn to get back Medicines Agency said last week it was and 22 were pulmonary embolisms. -
The Companion Test to SARS-Cov-2 Vaccination Innovating Rapid Testing to Preserve and Improve Life
TM The companion test to SARS-CoV-2 vaccination Innovating rapid testing to preserve and improve life Innovating rapid testing to preserve and improve life Leading the UK RTC Contents Introduction Page 03 The nature of SARS-CoV-2 testing has changed. Where Currently available tests detect antibodies targeting antibody tests were once chiefly used for charting the two different proteins on the SARS-CoV-2 virus: Introduction spread of infection within communities, today it is the Nucleocapsid or the Spike protein. However, almost 04 emerging as a key pillar of large-scale immunisation without exception, vaccine formulations are based on campaigns. the Spike protein. Vaccines and antibody tests converge on the same target However, there are stark differences between currently Testing for Nucleocapsid protein antibodies alone is 05 available antibody tests in both function and form. therefore of limited value. Though they may seem technical, these factors have Emerging evidence links prior infection with SARS-CoV-2 with immunity This short paper explains how rapid antibody testing significant implications for immunisation policy going focused on detecting the antibody response to the Spike 06 forward. protein, working hand in hand with vaccination, can help AbC-19™ Rapid Test The crucial difference is the antibody response that populations accelerate to herd immunity to SARS-CoV-2.. 06 the tests are evaluating. Trial of AbC-19™ Rapid Test with Vaccines 08 Summary 10 Contact 12 References 02 The companion test to SARS-CoV-2 vaccination 03 Vaccines and antibody tests Emerging evidence links prior infection converge on the same target with SARS-CoV-2 with immunity The SARS-CoV-2 virus comprises a single strand of RNA As a result, vaccine research has focused overwhelmingly on Two questions have dogged researchers since the outbreak of enveloped within four structural proteins. -
Dear Rook Irwin Sweeney Good Law Project Limited V Secretary of State
Rook Irwin Sweeney LLP Our ref: SS/335/10241.0086 107-111 Fleet Street Your ref: AMI:AIR;162 London EC4A 2AB 4 May 2021 By email: Dear Rook Irwin Sweeney Good Law Project Limited v Secretary of State for Health and Social Care v Abingdon Health Limited As you are aware, Abingdon Health plc (“Abingdon”) has not yet decided whether to participate in the judicial review proceedings that the Good Law Project (“GLP”) have brought against the Secretary of State for Health and Social Care, in which Abingdon is named as an Interested Party. Our client acknowledges the GLP’s right to challenge the Department of Health and Social Care’s (“DHSC’s”) processes, but is concerned about the basis on which the case is proceeding. Therefore, we would like to set out some points of clarification below, and have enclosed documents that we hope are useful. The test developed by Abingdon that is the subject of these proceedings is referred to as the “AbC-19TM Test”. Abingdon Health and its expertise 1. Throughout the proceedings to date, the GLP has made multiple disparaging statements about Abingdon’s expertise and its ability to develop a COVID-19 antibody test.1 Such statements have led the Court to conclude that “the extent to which Abingdon Health itself had any expertise is open to serious doubt”.2 In our view, there is no doubt at all as to Abingdon’s expertise, and it was eminently qualified for the task of developing a COVID-19 antibody test. On a full analysis of the facts, a Court would be likely to conclude the same. -
Operation Moonshot Proposals Are Scientifically Unsound
EDITORIALS BMJ: first published as 10.1136/bmj.m3699 on 22 September 2020. Downloaded from 1 University of Birmingham, Operation Moonshot proposals are scientifically unsound Birmingham, UK They could do more harm than good to people, populations, and the economy 2 University of Leicester. Leicester, UK Jonathan J Deeks, 1 Anthony J Brookes, 2 Allyson M Pollock3 3 Newcastle University, Newcastle, UK Correspondence to: J Deeks The polymerase chain reaction (PCR) swab test is balance of costs and harms against the potential [email protected] useful (but not perfect) for detecting SARS-CoV-2 benefits has not been evaluated Cite this as: BMJ 2020;370:m3699 virus RNA in symptomatic patients.1 However, Testing conundrums http://dx.doi.org/10.1136/bmj.m3699 problems arise using the test for purposes that Published: 22 September 2020 disregard symptoms or time of infection—namely, Now, Operation Moonshot has proposed that mass case finding, mass screening, and disease screening with less accurate point-of-care tests will surveillance. help “reduce the ‘R’ rate, keep the economy open and enable a return to normal life.”10 Could this work? This is because PCR is not a test of infectiousness. Rather, the test detects trace amounts of viral genome The Moonshot proposals are based exclusively on sequence, which may be either live transmissible computer modelling11 not empirical evidence. virus or irrelevant RNA fragments from previous Critically, the model considers repeated use of tests infection.2 When people with symptoms or who have that are positive only in infected people with high been recently exposed receive a positive PCR result viral loads of SARS-CoV-2. -
The Time the Children Didn't Go to School
THE TIME THE CHILDREN DIDN’T GO TO SCHOOL ANNABELLE HAYES FOREWORD ......................................................... 3 ACKNOWLEDGEMENTS .................................. 4 APRIL 2020 ............................................................ 5 MAY, 2020 ............................................................ 33 JUNE, 2020 .......................................................... 63 JULY, 2020 ......................................................... 102 AUGUST, 2020 .................................................... 110 SEPTEMBER, 2020 ............................................ 114 OCTOBER, 2020 ............................................... 129 NOVEMBER, 2020 ........................................... 152 DECEMBER, 2020 ............................................ 166 JANUARY, 2021 ................................................. 176 FEBRUARY, 2021 .............................................. 202 MARCH, 2021 .................................................... 223 AFTERWORD ................................................... 230 2 FOREWORD In March 2020, schools, nurseries and colleges in the United Kingdom were shut down in response to the ongoing coronavirus pandemic. By 20 March, all schools in the UK had closed to all children except those of key workers and children considered vulnerable. After a month of numbness at having all the children home, I started these diaries to document the unprecedented time when the children didn’t go to school. When the world stopped, the children didn’t – this records their -
Daily Report Tuesday, 12 January 2021 CONTENTS
Daily Report Tuesday, 12 January 2021 This report shows written answers and statements provided on 12 January 2021 and the information is correct at the time of publication (07:16 P.M., 12 January 2021). For the latest information on written questions and answers, ministerial corrections, and written statements, please visit: http://www.parliament.uk/writtenanswers/ CONTENTS ANSWERS 6 Children: Social Services 16 BUSINESS, ENERGY AND Coronavirus: Students 17 INDUSTRIAL STRATEGY 6 Educational Institutions: Carbon Emissions 6 Coronavirus 17 Electricity Generation 7 Further Education 18 Green Homes Grant Scheme 8 Higher Education: Fees and Green Homes Grant Scheme: Charges 18 Coronavirus 9 Pre-school Education: Hospitality Industry and Retail Coronavirus 19 Trade: Greater London 9 Remote Education 22 Hydrogen: Environment Schools: Discipline 24 Protection 10 Sikhs: Curriculum 24 Wind Power 10 Teachers: Absenteeism and Wind Power: Seas and Sick Leave 25 Oceans 11 FOREIGN, COMMONWEALTH CABINET OFFICE 12 AND DEVELOPMENT OFFICE 27 Port Infrastructure Fund 12 Developing Countries: UK-EU Trade and Cooperation Coronavirus 27 Agreement: Equality 13 India: Agriculture 27 DEFENCE 14 India: Religious Freedom 28 Armed Forces: Trees 14 Overseas Aid: Malaria 28 Members: Correspondence 15 Soft Power and External DIGITAL, CULTURE, MEDIA AND Affairs Department: Finance 29 SPORT 15 Sri Lanka: Religious Freedom 29 Culture: Greater London 15 HEALTH AND SOCIAL CARE 30 EDUCATION 15 Abortion 30 Children: Day Care 15 Abortion: Side Effects 31 Aspartame 31 Eating -
Whole Blood-Based Measurement of SARS-Cov-2-Specific T Cell
medRxiv preprint doi: https://doi.org/10.1101/2021.06.02.21258218; this version posted June 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Whole blood-based measurement of SARS-CoV-2-specific T cell responses reveals asymptomatic infection and vaccine efficacy in healthy subjects and patients with solid organ cancers Martin J. Scurr1,2, Wioleta M. Zelek3,4, George Lippiatt2, Michelle Somerville1, Stephanie E. A. Burnell1, Lorenzo Capitani1, Kate Davies5, Helen Lawton5, Thomas Tozer6, Tara Rees6, Kerry Roberts6, Mererid Evans7, Amanda Jackson7, Charlotte Young7, Lucy Fairclough8, Mark Wills9, Andrew D. Westwell10, B. Paul Morgan3,4, Awen Gallimore*1,3§ and Andrew Godkin*1,3,6§ 1 Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, UK. 2 ImmunoServ Ltd., Cardiff, UK 3 Systems Immunity University Research Institute, School of Medicine, Cardiff University, Cardiff, UK. 4 UK Dementia Research Institute Cardiff, Cardiff University, Cardiff, UK. 5 Radyr Medical Centre, Cardiff, UK. 6 Dept. of Gastroenterology & Hepatology, University Hospital of Wales, Heath Park, Cardiff, UK. 7 Velindre Cancer Centre, Cardiff, UK. 8 School of Life Sciences, University of Nottingham, Nottingham, UK. 9 Department of Medicine, Addenbrookes Hospital, University of Cambridge, Cambridge, UK. 10 School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK. * Corresponding Authors: Prof Andrew Godkin Division of Infection and Immunity Henry Wellcome Building Health Park Cardiff CF14 4XN Email: [email protected] Authorship note: (§) Aw.G and An.G contributed equally to this work.